Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
12-HETE activates the ILK/NF-κB pathway, which contributes to the suppression of cell apoptosis and suggests a key underlying mechanism that sustains the viability of ovarian cancer cells. 12-HETE promotes cell survival in ovarian cancer via triggering the integrin-linked kinase/NF-κB pathway. 12-HETE exhibits concentration-dependent protection against ovarian cancer cells' apoptosis. 12-HETE (1 µM) dramatically reduces the serum deprivation (SD)-induced caspase-3 activation. With an IC50 value of 1.13 µM, 12-HETE represses the increased activity of caspase-3 produced by SD in a concentration-dependent manner[1]. In ovarian cancer cells, 12-HETE (1 µM) promotes NF-κB activation and nuclear translocation via ILK[1]. 12-HETE causes cell death in human islets, lowers metabolic activity, and decreases insulin secretion. 12-HETE suppresses prostaglandin E1-induced elevation of intracellular cAMP levels while enhancing thrombin-induced bovine platelet aggregation. 12-HETE prevents the aggregation of washed platelets (WP)[2]. 12-HETE has a number of effects on neurons, including a reduction in glutamate release and calcium influx as well as a suppression of AMPA receptor (AMPA-R) activation[3].
|
---|---|
Cell Assay |
Cell Viability Assay[1]
Cell Types: Ovarian cancer OVCAR-3 and SKOV3 cells Tested Concentrations: 0, 0.2, 0.5, and 1 µM Incubation Duration: 0, 24, 48, 72, and 96 hrs (hours) Experimental Results: Inhibited the decrease in cell viability induced by SD in a dose-dependent manner. 1 µM 12-HETE treatment Dramatically mitigated the decrease in cell viability under conditions of SD. Western Blot Analysis[1] Cell Types: Ovarian cancer OVCAR-3 and SKOV3 cells Tested Concentrations: 1 µM Incubation Duration: Experimental Results: Led to increased levels of NF-κB p65 phosphorylation. Caused a significant increase in the protein levels of nuclear NF-κB p65, which was accompanied by diminished levels of NF-κB p65 in the cytoplasm. |
References |
[1]. Qian Liu, et al. 12-HETE facilitates cell survival by activating the integrin-linked kinase/NF-κB pathway in ovarian cancer. Cancer Manag Res. 2018 Nov 16;10:5825-5838.
[2]. Benedetta Porro, et al. Analysis, physiological and clinical significance of 12-HETE: a neglected platelet-derived 12-lipoxygenase product. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 1;964:26-40. [3]. Aidan J Hampson, et al. 12-hydroxyeicosatetrenoate (12-HETE) attenuates AMPA receptor-mediated neurotoxicity: evidence for a G-protein-coupled HETE receptor. J Neurosci. 2002 Jan 1;22(1):257-64. |
Molecular Formula |
C20H32O3
|
---|---|
Molecular Weight |
320.47
|
CAS # |
71030-37-0
|
Related CAS # |
12-HETE-d8;2525175-25-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CCCCC/C=C\CC(/C=C/C=C\C/C=C\CCCC(=O)O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1204 mL | 15.6021 mL | 31.2042 mL | |
5 mM | 0.6241 mL | 3.1204 mL | 6.2408 mL | |
10 mM | 0.3120 mL | 1.5602 mL | 3.1204 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.